Vimpat/Vimpat Injection

Vimpat/Vimpat Injection





Concise Prescribing Info
Monotherapy & adjunctive therapy in the treatment of partial-onset seizures w/ or w/o secondary generalization in adult & adolescent (≥16 yr) patients w/ epilepsy.
Dosage/Direction for Use
Monotherapy Initially 100 mg bid, increased to 150 mg bid after 1 wk. May be further increased at wkly interval by 50 mg bid (100 mg/day) depending on response & tolerability. Max recommended daily maintenance dose: 200 mg bid (400 mg/day). Conversion to monotherapy Initially 100 mg bid, increased to 150 mg bid after 1 wk. May be further increased by 50 mg bid (400 mg/day). Adjunctive therapy Initially 50 mg bid, increased to an initial therapeutic dose of 100 mg bid after 1 wk. May be further increased by 50 mg bid (100 mg/day). Max dose: 400 mg daily (200 mg bid). Initiation w/ a loading dose Initiated w/ a single loading dose of 200 mg, followed approx 12 hr later by a 100 mg bid (200 mg/day) maintenance dose, can be further increase by 50 mg bid wkly. Max: 400 mg. Severe renal impairment (CrCl ≤30 mL/min) & end-stage renal disease, hepatic impairment Max maintenance dose: 300 mg/day. Patient requiring hemodialysis Supplement of up to 50% of the divided daily dose directly after the end of hemodialysis.
May be taken with or without food.
Special Precautions
Dizziness & prolongations in PR interval may occur. Patients w/ conduction problems & severe cardiac disease eg, history of MI or heart failure. 2nd or 3rd degree AV block. Monitor for signs of suicidal ideation & behavior. Concomitant use w/ drugs known to be associated w/ PR prolongation. Renal, hepatic impairment & patients w/ end-stage renal disease. May have minor to moderate influence on the ability to drive & use machines. Pregnancy & lactation. Childn & adolescents <16 yr. Elderly.
Adverse Reactions
Dizziness, headache; diplopia; nausea. Depression, confusional state, insomnia; cognitive disorder, nystagmus, balance disorder, abnormal coordination, memory impairment, tremor, somnolence, dysarthria, attention disturbance, hypoesthesia, paraesthesia; blurred vision; vertigo, tinnitus; vomiting, constipation, flatulence, dyspepsia, dry mouth, diarrhea; pruritus; muscle spasms; gait disturbance, asthenia, fatigue, irritability, feeling drunk; fall, skin laceration; contusion.
Drug Interactions
Medicinal products known to be associated w/ PR prolongation (eg, carbamazepine, lamotrigine & pregabalin) & w/ class I antiarrhythmic drugs. May inhibit CYP2C19. Decreased overall systemic exposure w/ other antiepileptic drugs known to be enzyme inducers eg, carbamazepine, phenytoin, phenobarb. Increased AUC w/ omeprazole.
MIMS Class
ATC Classification
N03AX18 - lacosamide ; Belongs to the class of other antiepileptics.
Vimpat FC tab 100 mg
56's (P5,721/box)
Vimpat FC tab 150 mg
56's (P7,336.87/pack)
Vimpat FC tab 200 mg
56's (P9,782.89/box)
Vimpat FC tab 50 mg
56's (P3,145.01/box)
Vimpat Injection soln for infusion 10 mg/mL
20 mL x 5 × 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in